Search Within

Alexander Noor Shoushtari

  1. "2019"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (6)
  3. Research Letter (2)
  4. Editorial (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (19)
  2. Hematologic Malignancies, Division of (19)
  3. Melanoma Disease Management Team (19)
  4. Melanoma and Immunotherapeutics Service (19)
  5. Solid Tumor Oncology Division (19)
  6. GSK Faculty (8)

More Groups

People
  1. Jedd Wolchok (5)
  2. Michael Postow (4)
  3. Paul Chapman (4)
  4. Charlotte Ariyan (3)
  5. Christopher Barker (3)
  6. Jasmine Francis (3)

More People

Years
  1. 2019 (19)
Publications
  1. Journal of Clinical Oncology (6)
  2. Journal for ImmunoTherapy of Cancer (3)
  3. Advances in Therapy (1)
  4. British Journal of Ophthalmology (1)
  5. Cancer (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Biomed Central Ltd (3)
  3. Oxford University Press (2)
  4. Springer (2)
  5. American Association for Cancer Research (1)
  6. BMJ Publishing Group Ltd. (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors
    Journal Article

    Bhatia, A.; Birger, M.; Veeraraghavan, H.; Um, H.; Tixier, F.; McKenney, A. S.; Cugliari, M.; Caviasco, A.; Bialczak, A.; Malani, R.; more...
    Neuro-Oncology (2019)

    Fulltext@MSK | Save
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A.; Olszanski, A.; Hornyak, T.; Wolchok, J.; Vetrhus, S.; Handeland, K. R.; Kuryk, L.; Jaderberg, M.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma
    Meeting Abstract

    Shoushtari, A.; Middleton, M.; Stevens, N.; Evans, T.; Infante, J.; Sznol, M.; Anthoney, A.; Gupta, A.; Woodcock, V.; Wiseman, T.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • The impact of metastatic sites on checkpoint inhibitor outcomes in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Krieger, P.; Sanchez-Vega, F.; Schultz, N.; Shoushtari, A.
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Responders to anti-PD1 therapy: Long-term outcomes and responses to retreatment in melanoma (mel)
    Meeting Abstract

    Warner, A. B.; Palmer, J. S.; Shoushtari, A. N.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Wolchok, J. D.; Postow, M. A.; Chapman, P. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Therapeutic implications of a novel driver classification system for cutaneous and unknown primary melanomas
    Meeting Abstract

    Shoushtari, A. N.; Sanchez-Vega, F.; Kantheti, H.; Callahan, M. K.; Postow, M. A.; Barker, C. A.; Chatila, W. K.; Jonsson, P.; Ariyan, C. E.; Brady, M. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade
    Meeting Abstract

    Rapisuwon, S.; Shoushtari, A. N.; Gottesdiener, L. S.; Johnson, D. B.; Wang, D. Y.; Graham, G. T.; Goerlitz, D.; Berry, D.; Atkins, M. B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy
    Meeting Abstract

    Owen, C. N.; Larkin, J. M. G.; Shoushtari, A. N.; Carlino, M. S.; Blank, C. U.; Lee, B.; Mangana, J.; Atkinson, V.; Millward, M.; Zaman, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pharmacodynamic effect of IMCgp100 (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma
    Meeting Abstract

    Middleton, M. R.; Steven, N. M.; Evans, T. R. J.; Infante, J. R.; Hamid, O.; Shoushtari, A. N.; Corrie, P. G.; Anthoney, A.; Gupta, A.; Woodcock, V. K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma
    Meeting Abstract

    Middleton, M. R.; Steven, N. M.; Evans, T. R. J.; Infante, J. R.; Sznol, M.; Hamid, O.; Shoushtari, A. N.; Anthoney, A.; Gupta, A.; Woodcock, V. K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save